​

Funding Round

Series A - ReCode Therapeutics

Series A - ReCode Therapeutics

Investment Firm

Overview

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.

Announced Date

Mar 26, 2020

Funding Type

Series A

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

OrbiMed

OrbiMed

OrbiMed is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

4

Investor Name
Participant InvestorColt Ventures
Participant InvestorOrbiMed
Participant InvestorMPM Capital
Participant InvestorOUP (Osage University Partners)

Round Details and Background

ReCode Therapeutics raised $80000000 on 2020-03-26 in Series A

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 21, 2021
Series B - ReCode Therapeutics
11-80.0M
Jun 29, 2022
Series B - ReCode Therapeutics
5-120.0M
Jan 10, 2023
Venture Round - ReCode Therapeutics
1-10.0M
Sep 19, 2023
Series B - ReCode Therapeutics
12-50.0M

Recent Activity

There is no recent news or activity for this profile.